1h Free Analyst Time
According to the recently published report 'Adrenocorticotropic Hormone Receptor - Drugs In Development, 2022'; Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.Speak directly to the analyst to clarify any post sales queries you may have.
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.
The report 'Adrenocorticotropic Hormone Receptor - Drugs In Development, 2022' outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Discovery stages are 1, 2 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Undisclosed which include indications Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Endocrine Gland Disorders, IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease) and Unspecified.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
- The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development
- Crinetics Pharmaceuticals Inc
- Ferring Pharmaceuticals Inc
- Mallinckrodt Plc
- OMass Therapeutics Limited
- Upsher-Smith Laboratories LLC
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles
- AMZ-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- corticotropin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- corticotropin - Drug Profile
- Product Description
- Mechanism Of Action
- cosyntropin SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CRN-04894 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MC2 - Drug Profile
- Product Description
- Mechanism Of Action
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products
- Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones
- Featured News & Press Releases
- May 25, 2022: Crinetics Pharmaceuticals reports positive top-line results including strong adrenal suppression from CRN04894 phase 1 study multiple-ascending dose cohorts
- May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference
- Dec 02, 2021: Amzell and Amring Pharmaceuticals attending 2021 American Epilepsy Society Meeting in Chicago
- Nov 19, 2021: Amzell in collaboration With Amring Pharmaceuticals announce their lead product has entered Phase III clinical trial in the U.S. for treatment of infantile epileptic disease
- Nov 17, 2021: Options for those who suffer from rheumatoid arthritis as new research reflects the benefit of repository corticotropin injection (RCI) to Real-World Clinical Outcomes
- Aug 10, 2021: Crinetics Pharmaceuticals’ oral ACTH antagonist, CRN04894, demonstrates pharmacologic proof-of-concept with dose-dependent cortisol suppression in single ascending dose portion of phase 1 study
- Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmonary sarcoidosis
- May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting
- Feb 04, 2021: Crinetics Pharmaceuticals lead ACTH antagonist for congenital adrenal hyperplasia and Cushing’s disease (CRN04894) advances into phase 1 study
- Nov 16, 2020: AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease
- Oct 20, 2020: City of Rockford $10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy
- Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
- Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
- Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
- Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Crinetics Pharmaceuticals Inc, 2022
- Pipeline by Ferring Pharmaceuticals Inc, 2022
- Pipeline by Mallinckrodt Plc, 2022
- Pipeline by OMass Therapeutics Limited, 2022
- Pipeline by Upsher-Smith Laboratories LLC, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Crinetics Pharmaceuticals Inc
- Ferring Pharmaceuticals Inc
- Mallinckrodt Plc
- OMass Therapeutics Limited
- Upsher-Smith Laboratories LLC
